{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:18:54Z","timestamp":1785161934653,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX10103004"],"award-info":[{"award-number":["2017ZX10103004"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tsinghua University-Peking Union Medical College Hospital","award":["PTQH201911583"],"award-info":[{"award-number":["PTQH201911583"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Omadacycline showed potent activity against all Gram-positive pathogens:<jats:italic>S. aureus<\/jats:italic>MICs were low regardless of susceptibility to methicillin (methicillin-resistant<jats:italic>Staphylococcus aureus<\/jats:italic>, MRSA:<jats:italic>N<\/jats:italic>\u2009=\u200997, MIC<jats:sub>50\/90<\/jats:sub>0.12\/0.25\u2009mg\/L, 98.5% susceptible; methicillin-sensitive<jats:italic>Staphylococcus aureus<\/jats:italic>, MSSA:<jats:italic>N<\/jats:italic>\u2009=\u2009100, MIC<jats:sub>50\/90<\/jats:sub>0.12\/0.12\u2009mg\/L, 100.0% susceptible). Omadacycline was also very effective against \u03b2-haemolytic streptococci (MIC<jats:sub>50\/90<\/jats:sub>, 0.06\/0.12\u2009mg\/L), viridans group streptococci (MIC<jats:sub>50\/90<\/jats:sub>,&lt;0.03\/0. 06\u2009mg\/L), and enterococci (MIC<jats:sub>50\/90<\/jats:sub>, 0.03\/0.12\u2009mg\/L). Against<jats:italic>S. pneumoniae<\/jats:italic>, omadacycline was highly active regardless of penicillin-resistance (MIC<jats:sub>90<\/jats:sub>0.06\u2009mg\/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against<jats:italic>Enterobacterales<\/jats:italic>isolates (MIC<jats:sub>50\/90<\/jats:sub>, 2\/8\u2009mg\/L), inhibiting 81.7% of the isolates at \u22644\u2009mg\/L.<jats:italic>M. catarrhalis<\/jats:italic>isolates (MIC<jats:sub>50\/90<\/jats:sub>, 0.12\/0.25\u2009mg\/L) were fully susceptible to omadacycline at \u22640.5\u2009mg\/L.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R<jats:italic>S. pneumoniae<\/jats:italic>and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against<jats:italic>K. pneumoniae<\/jats:italic>isolates in the present study should be noted.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12866-020-02019-8","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T10:06:22Z","timestamp":1605521182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study"],"prefix":"10.1186","volume":"20","author":[{"given":"Meng","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanrong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kudinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-chun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"issue":"5","key":"2019_CR1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.chest.2017.04.162","volume":"152","author":"RE Corrado","year":"2017","unstructured":"Corrado RE, Lee D, Lucero DE, Varma JK, Vora NM. Burden of adult community-acquired, health-care-associated, hospital-acquired, and ventilator-associated pneumonia: New York City, 2010 to 2014. Chest. 2017;152(5):930\u201342.","journal-title":"Chest."},{"issue":"6","key":"2019_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1055\/s-0036-1592075","volume":"37","author":"JH Song","year":"2016","unstructured":"Song JH, Huh K, Chung DR. Community-acquired pneumonia in the Asia-Pacific region. Semin Resp Crit Care. 2016;37(6):839\u201354.","journal-title":"Semin Resp Crit Care"},{"key":"2019_CR3","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/IDR.S213296","volume":"12","author":"J Chen","year":"2019","unstructured":"Chen J, Li X, Wang W, Jia Y, Lin F, Xu J. The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort. Infect Drug Resist. 2019;12:2335\u201341.","journal-title":"Infect Drug Resist"},{"issue":"12","key":"2019_CR4","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1473-3099(18)30296-2","volume":"18","author":"A Chatterjee","year":"2018","unstructured":"Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis. 2018;18(12):e368\u2013e78.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2019_CR5","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1128\/AAC.01414-09","volume":"54","author":"CM Rubino","year":"2010","unstructured":"Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, et al. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob Agents Chemother. 2010;54(12):5180\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.rmed.2019.10.006","volume":"158","author":"YS Kwon","year":"2019","unstructured":"Kwon YS, Levin A, Kasperbauer SH, Huitt GA, Daley CL. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Resp Med. 2019;158:89\u201391.","journal-title":"Resp Med"},{"issue":"Supplement_1","key":"2019_CR7","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/ciz396","volume":"69","author":"FM Abrahamian","year":"2019","unstructured":"Abrahamian FM, Sakoulas G, Tzanis E, Manley A, Steenbergen J, Das AF, et al. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;69(Supplement_1):S23\u2013s32.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2019_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"2019_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","volume":"19","author":"MD Huband","year":"2019","unstructured":"Huband MD, Pfaller MA, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY antimicrobial surveillance Programme, 2017. J Glob Antimicrob Resist. 2019;19:56\u201363.","journal-title":"J Glob Antimicrob Resist"},{"issue":"10","key":"2019_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223599","volume":"14","author":"M Wu","year":"2019","unstructured":"Wu M, Tong X, Liu S, Wang D, Wang L, Fan H. Prevalence of methicillin-resistant Staphylococcus aureus in healthy Chinese population: a system review and meta-analysis. PLoS One. 2019;14(10):e0223599.","journal-title":"PLoS One"},{"issue":"11","key":"2019_CR12","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1128\/AAC.01536-15","volume":"59","author":"L Honeyman","year":"2015","unstructured":"Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59(11):7044\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"24","key":"2019_CR13","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6409\u201319.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"2019_CR14","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1128\/AAC.00470-19","volume":"63","author":"A Kaushik","year":"2019","unstructured":"Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(6):e00470\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2019_CR15","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1128\/AAC.01734-16","volume":"60","author":"KB Waites","year":"2016","unstructured":"Waites KB, Crabb DM, Liu Y, Duffy LB. In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human Mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother. 2016;60(12):7502\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2019_CR16","doi-asserted-by":"publisher","first-page":"e02262","DOI":"10.1128\/AAC.02262-18","volume":"63","author":"CG Carvalhaes","year":"2019","unstructured":"Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS. Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in mainland China, Hong Kong, and Taiwan: results from the SENTRY antimicrobial surveillance program (2013 to 2016). Antimicrob Agents Chemother. 2019;63(3):e02262\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2019_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/INF.0000000000001753","volume":"37","author":"KG Hulten","year":"2018","unstructured":"Hulten KG, Mason EO, Lamberth LB, Forbes AR, Revell PA, Kaplan SL. Analysis of invasive community-acquired methicillin-susceptible Staphylococcus aureus infections during a period of declining community acquired methicillin-resistant Staphylococcus aureus infections at a large children's hospital. Pediatr Infect Dis J. 2018;37(3):235\u201341.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2019_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/jac\/dkr561","volume":"67","author":"AP Johnson","year":"2012","unstructured":"Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A, et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother. 2012;67(4):802\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2019_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jama.2010.1115","volume":"304","author":"AJ Kallen","year":"2010","unstructured":"Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al. Health care-associated invasive MRSA infections, 2005-2008. Jama. 2010;304(6):641\u20138.","journal-title":"Jama."},{"issue":"7","key":"2019_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/cid\/ciu508","volume":"59","author":"BG Mitchell","year":"2014","unstructured":"Mitchell BG, Collignon PJ, McCann R, Wilkinson IJ, Wells A. A major reduction in hospital-onset Staphylococcus aureus bacteremia in Australia-12 years of progress: an observational study. Clin Infect. 2014;59(7):969\u201375.","journal-title":"Clin Infect"},{"key":"2019_CR21","unstructured":"Zhang D, Cui K, Wang T, Dong H, Feng W, Ma C, et al. Trends in and correlations between antibiotic consumption and resistance of Staphylococcus aureus at a tertiary hospital in China before and after introduction of an antimicrobial stewardship programme. Epidemiol Infect. 2018;147:1\u20136."},{"issue":"5","key":"2019_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1586\/14787210.2015.1023291","volume":"13","author":"R Serra","year":"2015","unstructured":"Serra R, Grande R, Butrico L, Rossi A, Settimio UF, Caroleo B, et al. Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus. Expert Rev Anti-Infect Ther. 2015;13(5):605\u201313.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"2019_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1749-7922-9-57","volume":"9","author":"M Sartelli","year":"2014","unstructured":"Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014;9(1):57.","journal-title":"World J Emerg Surg"},{"issue":"3","key":"2019_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jmv.24963","volume":"90","author":"H Oumei","year":"2018","unstructured":"Oumei H, Xuefeng W, Jianping L, Kunling S, Rong M, Zhenze C, et al. Etiology of community-acquired pneumonia in 1500 hospitalized children. J Med Virol. 2018;90(3):421\u20138.","journal-title":"J Med Virol"},{"issue":"2","key":"2019_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018709","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Zhou F, Li H, Xing X, Han X, Wang Y, et al. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. BMJ Open. 2018;8(2):e018709.","journal-title":"BMJ Open"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3389\/fmicb.2019.02546","volume":"10","author":"B Bai","year":"2019","unstructured":"Bai B, Lin Z, Pu Z, Xu G, Zhang F, Chen Z, et al. In vitro activity and heteroresistance of omadacycline against clinical Staphylococcus aureus isolates from China reveal the impact of omadacycline susceptibility by branched-chain amino acid transport system II carrier protein, Na\/pi cotransporter family protein, and fibronectin-binding protein. Front Microbiol. 2019;10:2546.","journal-title":"Front Microbiol"},{"key":"2019_CR27","unstructured":"Clinical and Laboratory Standards Institute. M100ED29E. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. Wayne: Clinical and Laboratory Standards Institute; 2019."},{"issue":"2","key":"2019_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","volume":"68","author":"AT Freire","year":"2010","unstructured":"Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140\u201351.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"2019_CR29","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1592\/phco.27.7.980","volume":"27","author":"JJ Schafer","year":"2007","unstructured":"Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. 2007;27(7):980\u20137.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"2019_CR30","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1179\/joc.2007.19.6.753","volume":"19","author":"BA Cunha","year":"2007","unstructured":"Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother. 2007;19(6):753\u20134.","journal-title":"J Chemother"},{"issue":"Supplement_1","key":"2019_CR31","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019;69(Supplement_1):S6\u2013S15.","journal-title":"Clin Infect Dis"},{"key":"2019_CR32","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421\u201334.","journal-title":"Future Microbiol"},{"key":"2019_CR33","unstructured":"Clinical and Laboratory Standards Institute M07ED11E. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 11th ed. Wayne: Clinical and Laboratory Standards Institute; 2018."},{"key":"2019_CR34","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 9.0","author":"EUCAST","year":"2019","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0. 2019 http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf: The European Committee on Antimicrobial Susceptibility Testing (EUCAST); 2019."},{"key":"2019_CR35","unstructured":"FDA. Recognized antimicrobial susceptibility test interpretive criteria for omadacycline: FDA, Silver Spring; 2018. https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products: [updated 14 Jun, 2019]."}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-02019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12866-020-02019-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-02019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T05:28:53Z","timestamp":1669613333000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-020-02019-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s12866-020-02019-8","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"350"}}